Skip to main content

Rein Therapeutics, Inc.

RNTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001420565

No open-market purchases or sales by Rein Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $42.5M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Rein Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Rein Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Rein Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Von Rickenbach Josef HDirector62,514May 28, 20261
Windsor James BrianSee Remarks27,046May 13, 20261
Voss Capital, LP10% Owner926,441IndirectNov 18, 20252
Voss Advisors GP, LLC10% Owner926,441IndirectNov 18, 20252
Cocke Travis W.10% Owner926,441IndirectNov 18, 20252
Voss Value-Oriented Special Situations Fund, LP10% Owner926,441IndirectNov 18, 20252
Voss Value Master Fund, LP10% Owner926,441IndirectNov 18, 20252
Musso Alan ADirector–Jul 23, 20250
Aivado ManuelDirector–Jul 23, 20250
Ambros Reinhard J.Director–Jul 23, 20250
Fairey WilliamDirector–Jul 23, 20250
University Of Texas/Texas Am Investment Management Co10% Owner1,746,549Jun 17, 20240
McKee WilliamDirector–Jun 17, 20220
Sigal Nolan HowardDirector–Jun 17, 20220
Bailey Jeffrey AllenDirector–Jun 17, 20220
Morrison Jodie PopeDirector–Jun 17, 20220
Vukovic VojoChief Medical Officer–Mar 30, 20220
Annis AllenSVP, Research–Mar 30, 20220
Wanstall RickSee Remarks–Mar 30, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 28, 2026 (view filing)May 21-277 daysLateVon Rickenbach Josef HDirectorPPurchaseCommon stock , $0.001 par value+47.1K$1.06+$49.7K+304.5%62.5K after4 lots
May 13, 2026 (view filing)Apr 3013 daysLateWindsor James BrianSee RemarksPPurchaseCommon stock , $0.001 par value+25.0K$1.00+$25.0K+1,221.9%27.0K after
Nov 18, 2025 (view filing)5:30 PM ETNov 144 daysVoss Capital, LP and 4 others10% OwnerPPurchaseCommon Stock, $0.001 par value+104.2K$1.22+$127.6K+12.7%926.4K after
Oct 28, 2025 (view filing)6:45 PM ETOct 24-284 daysVoss Capital, LP and 4 others10% OwnerPPurchaseCommon Stock, $0.001 par value+306.1K$1.38+$423.5K+157.8%500.0K after4 lots
Dec 9, 2024 (view filing)Dec 54 daysWindsor James BrianPresident and CEOPPurchase+400$2.24+$897.61New position161 after2 lots
Jun 17, 2024 (view filing)Jun 14-173 daysUniversity Of Texas/Texas Am Investment Management Co10% OwnerSSale−6.61K$3.26−$21.6K−0.4%1.75M after2 lots
Jun 12, 2024 (view filing)Jun 10-122 daysUniversity Of Texas/Texas Am Investment Management Co10% OwnerSSale−24.7K$3.27−$80.7K−1.4%1.75M after5 lots
Jun 7, 2024 (view filing)Jun 5-72 daysUniversity Of Texas/Texas Am Investment Management Co10% OwnerSSale−12.3K$3.29−$40.5K−0.7%1.78M after5 lots
May 14, 2024 (view filing)May 113 daysUniversity Of Texas/Texas Am Investment Management Co10% OwnerSSale−20.3K$4.21−$85.5K−1.1%1.79M afterAmended16 lots
Dec 18, 2023 (view filing)Dec 153 daysWindsor James BrianPresident and COOPPurchase+225$3.37+$758.25New position225 after
Nov 21, 2023 (view filing)Nov 201 dayWindsor James BrianPresident and COOPPurchase+5.08K$1.97+$10.0K+11,034.8%5.12K after